All In Biotech

Drug Trial Radar · NCT03392467

PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants

A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of PNEUMOSTEM for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia in Premature Infants

Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Aug 13, 2018

Primary completion

Jan 9, 2024

Study completion Oct 18, 2024

Sponsor

Lead sponsor
Medipost Co Ltd.Industry
Sponsor type
Industry
First posted
Jan 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, up to 13 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.

Conditions

  • Severe Bronchopulmonary Dysplasia

Interventions

  • PNEUMOSTEMBiological

    human umbilical cord blood-derived mesenchymal stem cells

  • PlaceboOther

    normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects who have severe BPD or are deadTime frame: 36 weeks postmenstrual age (PMA)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Asan medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.